Research Journal of Pharmacy and Technology

The current research focuses on solubility enhancement of poorly water soluble Biopharmaceutical Classification System (BCS) class-II drug Quetiapine, using carrier like plasdone K-29/32 and to evaluate its pharmacodynamic properties. Quetiapine solid dispersions were prepared using plasdone K-29/32 in different ratios by physical mixing and solvent evaporation techniques. Various physical parameters and invitro dissolution studies were performed for the prepared solid dispersions to find out the optimized formulation. The best formulation obtained was subjected to anti-anxiety and anti-schizophrenic activities by open field test and Morris water maze methods respectively on albino mice. The physical parameters evaluated for various Quetiapine solid dispersions were evaluated which were found to be in Indian Pharmacopoeial limits. From invitro dissolution studies, it was observed that the solid dispersion formulation QTS2 containing Quetiapine and plasdone K-29/32 in 1: 1 ratios prepared by solvent evaporation technique showed higher dissolution rate in less time when compared to all other formulations. QTS2 treated albino mice when subjected to open field test showed greater line crossings and less freezing time indicating its anti-anxiety effect. Whereas QTS2 treated mice when subjected to Morris water maze, have showed enhanced cognition which was indicated by faster identification of the maze immersed in water. This proves the positive effect of Quetiapine solid dispersions against negative symptoms of schizophrenic. Thus the solid dispersions prepared using plasdone K-29/32 as carrier enhanced solubility of Quetiapine which also increased its pharmacodynamic efficacy.